长效IL-7(rhIL-7-hyFc)增强CAR-iNKT细胞的抗骨髓瘤疗效
该研究在骨髓瘤异种移植小鼠模型中证实,BCMA CAR-iNKT细胞具有显著抗骨髓瘤活性;长效IL-7(rhIL-7-hyFc)可显著延长BCMA CAR-iNKT治疗小鼠的生存期并降低肿瘤负荷,且体外CRS实验中CAR-iNKT诱导的IL-6少于CAR-T。
要点
- BCMA CAR-iNKT细胞在骨髓瘤异种移植小鼠模型中显示显著抗骨髓瘤活性。
- rhIL-7-hyFc在初次和再攻击设置中均显著延长BCMA CAR-iNKT治疗小鼠生存期并降低肿瘤负荷。
- 体外CRS实验中CAR-iNKT诱导的IL-6少于CAR-T,提示CAR-iNKT治疗诱导CRS的可能性降低。
核心结论
- BCMA CAR-iNKT细胞可能是较BCMA CAR-T细胞更安全、有效的替代选择,且rhIL-7-hyFc可进一步增强BCMA CAR-iNKT的疗效。
研究设计与样本
- 研究在骨髓瘤异种移植小鼠模型中评估BCMA CAR-iNKT细胞的抗骨髓瘤活性,并在初次和再攻击设置中测试rhIL-7-hyFc的作用,同时进行体外CRS实验。
主要发现
- BCMA CAR-iNKT细胞在骨髓瘤异种移植小鼠模型中显示显著抗骨髓瘤活性。
- rhIL-7-hyFc在初次和再攻击设置中均显著延长BCMA CAR-iNKT治疗小鼠的生存期并降低肿瘤负荷。
- 体外CRS实验中,CAR-iNKT诱导的IL-6少于CAR-T,提示CAR-iNKT治疗诱导CRS的可能性降低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric antigen receptor (CAR) therapy because of its high expression in most MM, with limited expression in other cell types, resulting in favorable on-target, off tumor toxicity. The response rate to autologous BCMA CAR-T therapy is high; however, it is not curative and is associated with risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. Outcomes in patients treated with BCMA CAR-T cells (CAR-Ts) may improve with allogeneic CAR T-cell therapy, which offer higher cell fitness and reduced time to treatment. However, to prevent the risk of graft-versus-host disease (GVHD), allogenic BCMA CAR-Ts require genetic deletion of the T-cell receptor (TCR), which has potential for unexpected functional or phenotype changes. Invariant natural killer T cells (iNKTs) have an invariant TCR that does not cause GVHD and, as a result, can be used in an allogeneic setting without the need for TCR gene editing. We demonstrate significant anti-myeloma activity of BCMA CAR-iNKTs in a xenograft mouse model of myeloma. We found that a long-acting interleukin-7 (IL-7), rhIL-7-hyFc, significantly prolonged survival and reduced tumor burden in BCMA CAR-iNKT-treated mice in both primary and re-challenge settings. Furthermore, in CRS in vitro assays, CAR-iNKTs induced less IL-6 than CAR-Ts, suggesting a reduced likelihood of CAR-iNKT therapy to induce CRS in patients. These data suggest that BCMA CAR-iNKTs are potentially a safer, effective alternative to BCMA CAR-Ts and that BCMA CAR-iNKT efficacy is further potentiated with rhIL-7-hyFc.
引用
- O'Neal J, Cooper ML, Ritchey JK, et al. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc. Blood Adv. 2023. PMID: 37399471. doi:10.1182/bloodadvances.2023010032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。